Clinical Research
John C. Byrd, MD, Alvina D. Chu, MD, Steven Coutre, MD, Tony Lin, PharmD, Ying Luan, PhD, Fan Ny, NP, Jillian Settlemire, RN
Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy.
Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells.
Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.
The tissue expansion process using standard of care, saline-filled expanders is lengthy, inconvenient, and uncomfortable and may lead women to make the decision to decline breast reconstruction. The efficacy and safety of a novel, needle-free, patient-controlled tissue expander using CO2 as the filling medium was compared with the standard of care in the US-based XPAND study.
Cancer clinical research is essential to producing evidence-based clinical care that offers better treatment outcomes. Yet the recruiting and consenting process for cancer clinical trials can be challenging and lead to slow-accruing clinical research and dissatisfaction.
Annette Leon, PhD, MS, FACMG, Lauren Ryan, MS, LCGC, Lilian Servais, MS, LCGC, Jeroen van den Akker, PhD
We reviewed the personal and family histories of patients found to have multiple pathogenic or likely pathogenic mutations when tested clinically for 19 genes for hereditary breast and ovarian cancer and the implications for the patient and his or her family.
Patients with chemorefractory non-Hodgkin lymphoma (NHL) have poor response to standard therapy and short overall survival. The objectives of the phase 1 ZUMA-1 trial were to evaluate the safety and efficacy of KTE-C19, an autologous, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chemorefractory NHL.
Stomatitis is a common adverse event (AE) of mTOR inhibition. Nurses are critical in educating patients about and treatment of AEs.
Disease symptoms and treatment complications can profoundly affect quality of life (QOL) in patients (pts) with chronic lymphocytic leukemia (CLL). Here, we compare the QOL and hematologic function of patients treated with frontline ibr versus clb.
Previous studies have suggested that guideline-recommended therapy improves survival and reduces cost among patients with metastatic non–small cell lung cancer (mNSCLC). The purpose of this study was to explore the relationship between guideline-recommended initiation of therapy (GRI) in patients with mNSCLC and patient-reported outcomes (PROs), such as health-related quality of life (HRQOL) and patient-reported cancer symptoms.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512